Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
- New once-daily AUSTEDO XR regimen now approved in 6, 12, and 24 mg tablet strengths
- AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD) indications
- AUSTEDO is the only VMAT2 inhibitor with 3-year long-term data for both TD and HD chorea
